BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress

BioVersys AG, a Basel-based biopharmaceutical company, has initiated the Phase 3 clinical program for BV100, targeting ventilator-associated bacterial pneumonia. The Phase 3 trial follows successful Phase 2 results showing a 50% reduction in mortality in treating resistant infections. With trial sites established globally, patient dosing is anticipated soon, with results expected in late 2027.

BioVersys also completed a notable IPO in 2025, raising CHF 76.7 million, boosting its financial capacity to 2028. The company is advancing alpibectir in collaboration with GSK for tuberculosis treatment, with plans to initiate meningeal tuberculosis trials in 2026.

The company entered a collaboration with Shionogi for its BV500 program targeting non-tuberculous mycobacteria. BioVersys expects several key milestones in 2026, including interim results for the BV100 Phase 2b trial and progress in alpibectir research.